Saint Joseph Hospital
Saint Joseph Hospital
Lexington, Kentucky, United States34 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT05610163 | |
| Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05241860 | |
| Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, liposarcoma, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-09-17 | NCT05694871 | |
| S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04071457 | |
| Intravesical BCG vs GEMDOCE in NMIBC | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-09-15 | NCT05538663 | |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | Advanced Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Melanoma of Unknown Primary; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Acral Lentiginous Melanoma; Unresectable Melanoma; Unresectable Mucosal Melanoma | Active, not recruiting | Phase 2 | 2026-09-15 | NCT04462406 | |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-09-15 | NCT03516279 | |
| Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, gallbladder disorder, gallbladder neoplasm, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-14 | NCT04559139 | |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04266249 | |
| Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | esophageal adenocarcinoma | Active, not recruiting | Phase 3 | 2026-09-14 | NCT04248452 | |
| Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, anal canal squamous cell carcinoma, anal margin squamous cell carcinoma, anus basaloid carcinoma, anus disorder, anus neoplasm, cloacogenic carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04166318 | |
| A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, liver lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04115631 | |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate adenocarcinoma, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-10 | NCT05946213 | |
| To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate carcinoma, prostate disorder | Active, not recruiting | Phase 2 | 2026-09-04 | NCT04597359 | |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Metastatic Small Intestinal Adenocarcinoma; Stage III Small Intestinal Adenocarcinoma AJCC v8; Stage IIIA Small Intestinal Adenocarcinoma AJCC v8; Stage IIIB Small Intestinal Adenocarcinoma AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8 | Recruiting | Phase 2 | 2026-08-20 | NCT04205968 | |
| Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 3 | 2026-08-17 | NCT06745024 | |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | Cognition Disorders, Cognitive Dysfunction, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, cognitive disorder, neoplasm, psychiatric disorder, skin disorder | Active, not recruiting | Not applicable | 2026-07-30 | NCT05896189 | |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2026-07-10 | NCT04233866 | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Adnexal Diseases, Bartholin gland transitional cell carcinoma, Biliary Tract Neoplasms, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Gestational Trophoblastic Disease, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Nose Neoplasms, Otorhinolaryngologic Neoplasms, Parathyroid Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Pregnancy Complications, Neoplastic, Rare Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, acinar cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, adrenal gland pheochromocytoma, angiosarcoma, apocrine sweat gland neoplasm, basal cell carcinoma, basal cell neoplasm, bile duct disorder, bile duct neoplasm, biliary tract disorder, bladder adenocarcinoma, carcinoma, carcinosarcoma, cervical adenocarcinoma, cholangiocarcinoma, chordoma, colorectal squamous cell carcinoma, connective tissue neoplasm, cystadenocarcinoma, cystic, mucinous, and serous neoplasm, desmoid tumor, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial transitional cell carcinoma, endometrium neoplasm, epithelial neoplasm, extrahepatic bile duct carcinoma, extramammary Paget disease, fallopian tube adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroma, fibromyxoid tumor, fibrosarcoma, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, gastric squamous cell carcinoma, gastrointestinal stromal tumor, germinoma, gestational trophoblastic neoplasm, gonadal disorder, intrahepatic cholangiocarcinoma, lung adenocarcinoma, lung giant cell carcinoma, lung neoplasm, lung neuroendocrine neoplasm, lung sarcomatoid carcinoma, major salivary gland carcinoma, malignant endocrine neoplasm, minimally invasive lung adenocarcinoma, mixed neoplasm, mouth disorder, mucinous adenocarcinoma, mucinous adenocarcinoma of the appendix, mucinous cystadenocarcinoma, nasal cavity adenocarcinoma, nasal cavity carcinoma, nasal disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, nerve sheath neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, oral cavity carcinoma, otorhinolaryngologic disease, ovarian adenocarcinoma, ovarian cancer, ovarian disorder, ovarian germ cell tumor, ovarian mucinous adenocarcinoma, ovarian squamous cell carcinoma, ovarian transitional cell carcinoma, pancreas disorder, pancreatic acinar cell carcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paraganglioma, paranasal sinus carcinoma, paranasal sinus disorder, paranasal sinus neoplasm, parathyroid gland carcinoma, parathyroid gland disorder, peripheral nervous system disorder, peripheral nervous system neoplasm, pheochromocytoma, placental choriocarcinoma, pregnancy disorder, primitive neuroectodermal tumor, pseudomyxoma peritonei, respiratory system disorder, respiratory tract neoplasm, sarcoma, scrotum squamous cell carcinoma, seminal vesicle adenocarcinoma, seminoma, small intestine adenocarcinoma, somatostatinoma, spindle cell neoplasm, squamous cell carcinoma of penis, squamous cell carcinoma of the small intestine, testicular non-seminomatous germ cell tumor, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, trachea carcinoma, transitional cell carcinoma, trophoblastic neoplasm, undifferentiated carcinoma of esophagus, undifferentiated carcinoma of nasopharynx, undifferentiated carcinoma of stomach, ureter adenocarcinoma, ureter squamous cell carcinoma, urethra adenocarcinoma, urethra squamous cell carcinoma, vaginal adenocarcinoma, vascular cancer, vulva cancer, vulvar carcinoma, vulvar disease | Active, not recruiting | Phase 2 | 2026-06-17 | NCT02834013 | |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-06-10 | NCT05561387 | |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-06-03 | NCT05642572 | |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-05-22 | NCT06998940 | |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | Malignant Solid Neoplasm | Recruiting | Not stated | 2026-05-05 | NCT04871542 | |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-04-23 | NCT04852887 | |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | infiltrating bladder urothelial carcinoma | Active, not recruiting | Phase 2 | 2026-04-13 | NCT03609216 |